Stock CSTL CASTLE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Castle Biosciences, Inc.

Equities

CSTL

US14843C1053

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
21.53 USD +5.85% Intraday chart for Castle Biosciences, Inc. +9.79% -0.23%
Apr. 08 Castle Biosciences Insider Sold Shares Worth $441,853, According to a Recent SEC Filing MT
Apr. 04 Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
BU
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
BU
Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
BU
Castle Biosciences Insider Sold Shares Worth $441,853, According to a Recent SEC Filing
MT
Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
BU
Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress
CI
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
BU
Castle Biosciences Announces Updates to its Board of Directors
BU
Castle Biosciences, Inc. Announces Board Changes
CI
Castle Biosciences, Inc. - Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx-Melanoma Test Result Were Recurrence Free at Three Years
AQ
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
BU
Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
BU
Castle Biosciences - Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
AQ
Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
BU
Castle Biosciences, Inc. Announces the Publication of an Expert Consensus Article in the Journal of Clinical and Aesthetic Dermatology
CI
New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
BU
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences and MedTech Investor Forum
AQ
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
BU
Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
BU
Castle Biosciences - In Novel Cohort, New Data Confirms DecisionDx-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CSTL Stock
  4. News Castle Biosciences, Inc.